Alteration of fecal flora was prospectively studied in 21 children receiving imipenem-cilastatin therapy under protocol for therapy of infections. Although no profound reduction in facultative or anaerobic flora was observed, qualitative and quantitative increases in organisms which were resistant or less susceptible to imipenem occurred. Of 21 patients, 13 (62%) had increases in counts of Enterococcus spp. of at least 103 organisms per g (wet weight) of stool, and 7 (33%) had acquisition of or similar increases in counts of Candida species. No change in susceptibility of isolates to imipenem was demonstrable during therapy. However, the MICs for 50 and 90% of the strains of Enterococcus spp. (2 and 8 ,ug/ml, respectively) were higher than those previously reported.
Therapy with broad-spectrum antimicrobial agents may result in significant alteration in the normal intestinal microbial flora of animals and humans (2, 12) . Of the newer beta-lactam and monobactam agents, ceftazidime, ceftriaxone, cefoperazone, and aztreonam have each been shown to markedly reduce facultative gram-negative bacillary flora (1, 5, 10) . Suppression of anaerobic fecal flora has been demonstrated during ceftriaxone and cefoperazone therapy. Moxalactam profoundly alters fecal microbial flora; colonization and superinfection with Enterococcus, Pseudomonas, and Candida species have been reported to occur in normal and immunocompromised hosts concomitant with moxalactam therapy (9, 14 ; M. C. Fisher and S. S. Long, Program Abstr. 22nd Intersci. Conf. Antimicrob. Agents Chemother., abstr. no. 104, 1982). As new broader-spectrum, more potent antimicrobial agents become available, choosing among them may depend as much on how little they disrupt flora as on how active they are. Imipenem (N-formimidoyl thienamycin), a new betalactam agent, has activity against an extremely broad spectrum of microorganisms. It has superior activity compared with that of aminoglycosidic agents and broad-spectrum cephalosporin agents for Enterococcus species, and certain Enterobacter, Proteus, Serratia, and Pseudomonas species (7, 8, 11) . We performed a prospective study of patients receiving imipenem-cilastatin (in a 1:1 ratio) for treatment of infections to determine the effect of therapy on fecal flora.
MATERIALS AND METHODS
Study patients. Children aged 3 months to 13 years were enrolled in a study of the efficacy and safety of imipenem for treatment of bacterial infections severe enough to require hospitalization and antibiotic therapy administered by parenteral route. Children with underlying illnesses, those with central nervous system infections, and those who had received antimicrobial therapy within 14 days preceding hospitalization were excluded. Institutional approval and informed written consent from all parents and some patients were obtained. Imipenem dosage for children 3 years of age or greater was 15 mg/kg of body weight every 6 h, and for those less than 3 years of age the dose was 25 mg/kg of body * Corresponding author.
weight every 6 h. Therapy was continued until infection was cured or sufficiently controlled such that orally administered therapy was appropriate.
Collection of specimens and technique of culture. Stool specimens of 1 g were taken before initiation of therapy, every 2 to 3 days during therapy, and at the end of therapy. If voluntary collection of a stool sample was not possible at the time of initiating therapy, a rectal-swab specimen of approximately 0.5 g of fecal material was obtained by one investigator. Subsequently, only passed stool specimens were accepted. All specimens were processed immediately after collection by one investigator. Fecal specimens obtained by swab were put into 3 ml of VPI (Virginia Polytechnic Institute and State University) anaerobic salt broth and homogenized by vortex swirl, and 0.1 ml was spread by glass rod onto each medium. Homogenized specimens prepared after voluntary or involuntary collection were serially diluted in phosphate-buffered saline, and 0.1 ml was inoculated onto selective media to equal final dilutions of 10-3, 10-5, and 10'. The following media were used for recovery of facultative and aerobic organisms: Trypticase-soy sheepblood agar (BBL Microbiology Systems, Cockeysville, Md.), enterococcoceal agar (BBL), MacConkey agar (BBL), cetrimide agar (Difco Laboratories, Detroit, Mich.), and Trypticase-soy sheep-blood agar containing 10 ,ug of imipenem per ml (imipenem agar). For the recovery of anaerobic bacteria, specimens were inoculated onto prereduced media and incubated 48 h at 38°C in anaerobic GasPak jars (BBL). Schaedler KV agar (BBL), lactobacillus agar (BBL), cycloserine-cefoxitin-fructose agar, and imipenem agar were used.
After incubation, isolates were identified by standardized laboratory methods. Colonies were counted and quantified as CFUs per gram (wet weight) of stool. Minimum counts detectable were 103 CFU/g. Culture results for each subject were compared with his or her results from prior sampling. An increase or decrease of a count was defined as a 3-log10 or greater change in CFUs per gram. To assign categories of change when organisms were acquired or disappeared, negative cultures were arbitrarily assigned a count of 102 CFU/g. Only a 3-log change (i.e., 105 CFU/g on one culture) was considered significant. Persistence was defined as either recovery of the same isolate without 3-log change or the ANTIMICROB. AGENTS CHEMOTHER. Table 2 ). The MIC50 of imipenem for enterococci was 2 pLg/ml or lower, and the MIC90 was 8 ,ug/ml; the MIC50 for Proteus species was 2 ,ug/ml, and the MIC90 was 4 ,ug/ml; the MIC50 for E. coli was 0.5 pLg/ml, and the MIC90 was 1 ,ug/ml.
By the broth-disk method, anaerobic gram-negative bacilli were all susceptible to 10 p.g of imipenem per ml. The susceptibilities of organisms to imipenem according to time of isolation during therapy were compared (Table 2 ). There was no difference in susceptibility to imipenem for isolates recovered from pretreatment and end-of-therapy cultures (MIC50 of imipenem for all isolates was 2 ,ug/ml at both samplings). For 19 isolate pairs (same isolate recovered from pretreatment and end-of-therapy cultures of a patient), there was no change in susceptibility to imipenem during therapy (MIC50 of imipenem was 2 Vtg/ml at both samplings).
DISCUSSION
The potential advantage ascribed to the new agent imipenem over broad-spectrum cephalosporins is the inclusion of Pseudomonas species, Enterococcus species, and several members of Enterobacteriaceae in the spectrum of drug activity. This expanded spectrum also poses potential disadvantages. In this study of the effects of a short course of imipenem-cilastatin therapy on fecal flora, no profound overall reduction of normal aerobic, anaerobic, or facultative organisms occurred. This is in constrast to findings for moxalactam and cefoperazone given over a similar time period and is almost surely related to a coinparatively higher degree of biliary excretion of the latter drugs (10; Fisher and Long, 22nd ICAAC). Within 3 days of beginning imipenemcilastatin therapy, however, qualitative or quantitative increases in resistant or less susceptible organisms were observed. The majority of patients (62%) had at least a 1000-fold increase in fecal enterococcal colony counts. Counts of P. mirabilis and Pseudomonas species increased, and one-third of patients had an increase in isolates of Candida species. Except for Candida species, no imipenem-resistant (MIC, .10 p.g/ml) organism was found at the beginning of therapy, and none emerged during therapy. There was no change over time in susceptibility to imipenem among isolates which increased in numbers or which were acquired during therapy. However, imipenem generally had higher than expected MICs for these organisms. In three reports (4, 6, 8) , MIC50s of imipenem for enterococci were 0.5, 0.78, and 1 pLg/ml. MICs of imipenem were higher for 78% of enterococci tested in our study. The MIC90 of imipenem for enterococci has been said to be 2 p.g/ml (4). The MIC90 for enterococci in our study was 8 p.g/ml. Likewise, MICs of imipenem for the majority of the Enterobacteriaceae which increased during therapy were greater than 1 p.g/ml and greater than MIC50s reported for their respective species (4, 11) . There was no difference in susceptibility for the same isolate when recovered from agar with and without imipenem.
These data suggest that organisms which are relatively less susceptible to imipenem (such as Enterococcus species and some Enterobacteriaceae) or resistant to imipenem (such as Candida species) increase in fecal flora early in the course of therapy. Although no patient in this study experienced secondary infection as a consequence of these alterations, all patients were healthy at the onset of their infections and had not had recent courses of antimicrobial or anticancer agents; most received therapy for less than 1 week. The data also differ from those reported on the in vitro susceptibility of Enterococcus species to imipenem and question the anticipated efficacy of the drug for treating patients with infections due to this microorganism.
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